Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec 19:8:354.
doi: 10.3389/fendo.2017.00354. eCollection 2017.

Editorial: Bone: Endocrine Target and Organ

Giacomina Brunetti  1 , Patrizia D'Amelio  2 , Malgorzata Wasniewska  3 , Giorgio Mori  4 , Maria Felicia Faienza  5
Affiliations
Editorial

Editorial: Bone: Endocrine Target and Organ

Giacomina Brunetti et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: PTH; adipose tissue; bone and bones; glucagon-like peptide-1; hormones; immune cells.

PubMed Disclaimer

References

    1. Yoda K. Bone as an endocrine organ: diabetic bone disease as a cause of endocrine disorder via osteocalcin, FGF23 secreted from osteocyte/osteoblast. In: Inaba M, editor. Musculoskeletal Disease Associated with Diabetes Mellitus. Tokyo: Springer; (2016) 113–23.10.1007/978-4-431-55720-3_8 - DOI
    1. Sheu WH, Brunell SC, Blase E. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Res Clin Pract (2016) 114:160–72.10.1016/j.diabres.2015.12.004 - DOI - PubMed
    1. Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia (2016) 59(2):266–74.10.1007/s00125-015-3795-1 - DOI - PMC - PubMed
    1. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab (2016) 18(3):249–57.10.1111/dom.12602 - DOI - PMC - PubMed
    1. Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept (2010) 159(1–3):61–6.10.1016/j.regpep.2009.06.010 - DOI - PubMed

Publication types